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Abstract
Background: Micafungin and caspofungin, which are both echinocandins, elicit their antifungal effects by suppressing
the synthesis of β-D-glucan, an essential component of fungal cell walls. If micafungin is not effective against a fungal
infection, is it unreasonable to switch to caspofungin?
Case presentation: An 80-year-old Asian man presented to our hospital with brain and lung abscesses. Klebsiella
pneumonia and Escherichia coli were identified by sputa culture and Streptococcus mitis was identified in the brain
abscess culture obtained by drainage surgery. He was treated with antibiotics and both abscesses shrank after the
treatment. But he continued to have a high fever and Candida glabrata was identified by blood culture. The origin of
the infection was not clarified and micafungin was administered intravenously. The fungus showed poor susceptibility
to micafungin; we then switched the antifungal from micafungin to caspofungin. After caspofungin treatment, his
body temperature remained below 37 °C and his β-D-glucan levels decreased remarkably.
Conclusions: In vitro, micafungin is considered more effective against C. glabrata because its minimum inhibitory
concentration against C. glabrata is lower than that of caspofungin. However, in vivo, there is no significantly different
effect between the two drugs. When micafungin is not effective against candidiasis, a switch to caspofungin might be
applicable because the pharmacokinetics in each echinocandin is slightly different.
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Background
Antifungal agents that are currently used for deep fungal
infections include polyene macrolide derivatives (ampho-
tericin B), azole antifungals (imidazoles and triazoles), and
echinocandins. Echinocandins are recommended as the
primary therapy for invasive candidiasis [1], and resistance
to echinocandins remains low, at less than 3 %, in Candida
albicans [2]. However, cases of echinocandin-resistant
Candida glabrata are increasing with cross-resistance to
azole antifungal agents [3, 4]. Here, we report a case of
successful treatment for C. glabrata infection that showed
poor sensitivity to micafungin (MCFG), which is an
echinocandin.
Case presentation
An 80-year-old Asian man presented to our hospital
with left hemiparesis; a manual muscle test revealed
motor weaknesses of 2+/5 in his upper limbs and 4/5 in
his lower limbs. Magnetic resonance imaging (MRI)
demonstrated a brain abscess in his right frontal lobe
(motor area), and both a chest X-ray and a computed
tomography (CT) scan showed a lung abscess in the
lower lobe of his right lung (Fig. 1a, day 0). He had
undergone partial resection of his stomach due to gastric
cancer 11 years ago, but he did not take anti-cancer
drugs and no recurrence was identified. The drugs he
had been taking were 50 mg of sodium ferrous citrate,
1500 μg vitamin B12, 20 mg esomeprazole, and 2.5 mg
amlodipine. His medical history did not indicate an
immune deficiency disorder. No organ dysfunction was
indicated from laboratory data. But mild anemia was
identified: his hemoglobin value was 11.9 g/dl (normal
range 13.5 to 17.6), hematocrit 35.0 % (39.8 to 51.8),
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iron (Fe) 49 mg/dl (50 to 170), and ferritin 98.9 ng/ml
(21 to 282). Because he was not able to eat enough food
for 1 week before admission, his nutritional status was
poor: serum total protein 6.1 g/dl (normal range 6.7 to
8.3), albumin 3.2 g/dl (3.8 to 5.1), total cholesterol 148
mg/dl (150 to 219), and triglyceride 126 mg/dl (50 to
150).
Days 0–10
On admission, he was administered clindamycin (CLDM;
600 mg twice a day) because we were considering aspi-
ration pneumonia. However, this was switched to imipe-
nem/cilastatin sodium (IMP/CS; 0.5 g twice a day) on day
6 post-admission because Klebsiella pneumoniae and
Escherichia coli were identified by sputa culture (Fig. 1b).
Days 11–20
After the antibiotic was changed to IMP/CS, his body
temperature gradually elevated, his serum C-reactive
protein (CRP) level also increased to 7.8 mg/dl (normal
range <0.3 mg/dl), and his left hemiparesis worsened. To
address these symptoms, a surgical aspiration of his
brain abscess was performed under local anesthesia on
day 12. Although his left hemiparesis mildly improved
after the surgery and the follow-up chest X-ray and CT
scan showed that he was recovering from pneumonia
(Fig. 1a, Day 16), high fever continued after the surgery
in spite of the IMP/CS treatment. Streptococcus mitis
was identified in the brain abscess culture, and a blood
culture performed on day 16 indicated he had a simul-
taneous fungal infection. The antibiotic was changed to
cefepime dihydrochloride hydrate (CFPM; 1 g twice a
Fig. 1 Chronological changes in the brain and lung abscesses. a Image studies: top, chest computed tomography scan; middle, chest X-ray; and bottom,
head magnetic resonance imaging with contrast medium. b Alterations in body temperature (black), C-reactive protein levels (blue), and β-D-glucan levels
(green) in response to the changes in antibiotics and antifungals. Daily doses: clindamycin 600 mg, twice a day; imipenem/cilastatin sodium 0.5 g, twice a
day; cefepime dihydrochloride hydrate 1 g, twice a day; cefotiam hydrochloride 1 g, twice a day; levofloxacin hydrate 500 mg, once a day; ceftazidime
hydrate 1 g, twice a day; fosfluconazole 800 mg, once a day on the first day, and 400 mg, once a day after second day; micafungin sodium 150 mg, once
a day; and caspofungin acetate 70 mg, once a day on the first day, and 50 mg, once a day after second day. The red horizontal line in the graph indicates
the body temperature level of 37 °C and CRP level of 10 mg/dl. CAZ ceftazidime hydrate, CFPM cefepime dihydrochloride hydrate, CLDM clindamycin,
CPFG caspofungin acetate, CRP C-reactive protein, CTM cefotiam hydrochloride, CTX cefotaxime, F-FLCZ fosfluconazole, IMP/CS imipenem/cilastatin so-
dium, LVFX levofloxacin hydrate, MCFG micafungin sodium
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day) targeting a Gram-positive coccus and fosflucona-
zole (F-FLCZ; 800 mg once a day on the first day and
400 mg once a day after second day) treatment was
added for fungal infection. Despite these treatments, he
still had a high body temperature (39.7 °C) on day 20
(Fig. 1b). At this time, a central venous catheter was
inserted in his right subclavian vein for parenteral nutri-
tion because he was unable to get sufficient nutrients
through oral intake.
Days 21–30
On day 21, 4 days after CFPM treatment started, his
body temperature elevated again to 39.6 °C and his
serum CRP level drastically increased. He had difficulty
in breathing and was intubated with artificial respirator
assistance because his chest X-ray showed diffuse inter-
stitial pneumonia (Fig. 1a, Day 23) and E. coli was still
identified in sputa culture. The antibiotic was switched
back to IMP/CS (0.5 g twice a day) targeting E.coli, and
cefotiam hydrochloride (CTM; 1 g twice a day) was used
for brain abscess treatment because we considered it
had good transitivity of the antibiotic to the cerebro-
spinal fluid. In addition, C. glabrata, which is resistant
to F-FLCZ, was detected via the blood culture per-
formed on day 16, and his level of β-D-glucan was ex-
tremely high at 3634 pg/ml (normal range <20 pg/ml).
Then, he received combination treatments of MCFG
(150 mg once a day), IMP/CS (0.5 g twice a day), and
CTM (1 g twice a day) because of multiple infections
resulting from fungi and from both Gram-negative bacil-
lus and Gram-positive coccus bacteria (Fig. 1b).
Days 31–50
A chest X-ray on day 32 displayed an improvement in
his diffuse interstitial pneumonia (Fig. 1a), and he was
extubated. His antibiotic treatments with IMP/CS and
CTM were changed to cefotaxime (CTX; 1 g twice a
day) because two strong antibiotics were used for 1
week. However, his CRP rose rapidly to 7.4 mg/dl from
4.7, and the antibiotic was switched back to IMP/CS (0.5
g twice a day) and CTM (1 g twice a day). Another 1
week of combination treatment of IMP/CS and CTM
was performed. His body temperature was constantly el-
evated over 37.0 °C and his CRP never decreased less
than 5.0 mg/dl. Then, levofloxacin hydrate (LVFX; 500
mg once a day), which was classified as quinolone anti-
biotic, was applied from day 43. During the period of
MCFG administration, his body temperature fluctuated
between 37 and 38 °C and his CRP level varied between
5 and 10 mg/dl. On day 43, his level of β-D-glucan de-
creased to 1732 pg/ml. MRI on day 46 revealed that his
brain abscess had almost completely disappeared (Fig. 1a,
day 46) and a chest X-ray demonstrated amelioration of
his pneumonia (Fig. 1a, Day 49). However, on day 49, his
body temperature climbed to 38 °C, his CRP level in-
creased to 9.8 mg/dl, and his β-D-glucan level elevated
to 1947 pg/ml. To address these symptoms, on day 51,
the MCFG was switched to caspofungin (CPFG; 70 mg
once a day on the first day and 50 mg once a day after
second day) and ceftazidime hydrate (CAZ; 1 g twice a
day) treatment was added (Fig. 1b).
Days 51–72
Three days after initiating the CPFG and CAZ treat-
ments, his body temperature began decreasing and
never exceeded 37 °C after day 55. His CRP level also
rapidly decreased after the initiation of CPFG treat-
ment; it dropped within the normal range and did
not increase again after day 63. The central venous
catheter was removed on day 65 because he could in-
gest fully. His β-D-glucan level decreased to 1000 pg/
ml (Fig. 1b), and C. glabrata was not identified in the
blood culture performed on day 69.
At day 70, a chest X-ray and CT scan demonstrated
successful treatment of his lung abscess and pneumonia
(Fig. 1a). When he was discharged from our hospital on
day 73, he had regained his motor function (4−/5 in
his left upper limb and 5/5 in his left lower limb by a
manual muscle test).
Conclusions
In our patient, the risk factors for candidemia included
partial resection of stomach causing Fe deficiency
anemia, malnutritional status on admission, age, and the
long-term usage of antibiotics. C. glabrata is one of the
prevalent causes of candidemia, and it exhibits poor sus-
ceptibility to azole antifungals, acquiring resistance rap-
idly [5, 6]. Instead, echinocandins are recommended
when Candida infection is suspected [1]. Anidulafungin
(ANFG), CPFG, and MCFG are all echinocandins with
similar antifungal activity spectra [7–9], but only CPFG
and MCFG are authorized in Japan. In in vitro studies,
the minimum inhibitory concentration against C. glab-
rata was higher in CPFG than in ANFG or MCFG, and
MCFG was the most potent agent against C. glabrata
[9–11]. However, the clinical outcomes of patients with
systemic candidiasis due to C. glabrata were not signifi-
cantly different if they were treated with MCFG or with
CPFG [12].
The level of serum β-D-glucan increased in spite of
MCFG treatment in our patient; however, we switched
the antifungal to CPFG, another echinocandin, rather
than changing to a different class of antifungals because
echinocandins suppress β-D-glucan synthesis better
than any other antifungals [13]. Notably, CPFG treat-
ment was dramatically effective in our case. Spreghini
et al. found that, in the absence of human serum, the
susceptibilities of C. glabrata to MCFG and to CPFG
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were not statistically different from one another,
whereas, in the presence of human serum, C. glabrata
was more susceptible to CPFG than to MCFG (p <0.05)
[14]. In their study using mice, CPFG started to be ef-
fective after 2 days of treatment, while after 6 days, the
lowest effective doses were 0.25, 1, and 5 mg/kg/day for
CPFG, MCFG, and ANFG, respectively [14]. Our case
clearly demonstrates the effectiveness of CPFG in a pa-
tient with C. glabrata infection that showed resistance
to MCFG. In echinocandin pharmacokinetics, the
protein-binding form of the drug constitutes 99.8 % in
MCFG and 97 % in CPFG, and the clearance of CPFG
from the human body is much slower than that of
MCFG [13]. The lower percentage of protein-binding
form and slower excretion of CPFG may help it main-
tain an effective drug concentration against C. glabrata
for longer than MCFG.
In fact, invasive candidiasis was successfully treated
by CPFG in our case, but we do not conclude that
CPFG is more effective than MCFG for C. glabrata in-
fection because the in vivo antifungal activity, pharma-
cokinetics, and toxicity profiles are slightly different in
each echinocandin [15]. We considered that the sensi-
tivity pattern of the Candida to echinocandins in our
patient was that the C. glabrata in our patient was ba-
sically sensitive to echinocandins, and it was more sen-
sitive to CPFG than to MCFG. Some advantages of
MCFG treatment are that serious side effects rarely
occur and it can be used when the patient has mild to
severe hepatic dysfunction [13, 16]. Unfortunately,
CPFG is the only echinocandin for which dosage reduc-
tion is recommended if patients have even mild hepatic
dysfunction [1]. Therefore, MCFG should still be the
first drug choice for candidemia; however, if it is not ef-
fective, early replacement with CPFG should be consi-
dered, rather than adding another kind of antifungal
agent.
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